Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2021 02:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics publicerar årsredovisning för 2020

Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2020. Årsredovisningen finns tillgänglig på IBTs hemsida ibtherapeutics.com under avsnittet...
April 09, 2021 02:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics publishes Annual Report for 2020

Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2020. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media –...
April 01, 2021 09:00 ET | Source: Infant Bacterial Therapeutics AB

Kallelse till årsstämma i Infant Bacterial Therapeutics

Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma tisdagen den 4 maj 2021. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
April 01, 2021 09:00 ET | Source: Infant Bacterial Therapeutics AB

Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, May 4, 2021. In light of the coronavirus, the Annual General Meeting is conducted through...
February 10, 2021 09:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics meddelar att rekryteringen till den första delen av fas III studien är klar - en uppdatering om den kliniska utvecklingen av IBP-9414

Infant Bacterial Therapeutics (IBT) kan idag meddela att företaget nu har uppnått en viktig milstolpe genom att ha rekryterat 300 barn i den pågående kliniska fas III-studien av IBP-9414. Detta...
February 10, 2021 09:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics announces that the recruitment to the first stage of the Phase III Connection Study is completed - an update about the clinical development of IBP-9414

Infant Bacterial Therapeutics (IBT) announces that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP-9414. This in...
February 09, 2021 14:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Japan

Infant Bacterial Therapeutics AB (IBT) meddelar idag att det Japanska Patentverket beslutat utfärda ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar...
February 09, 2021 14:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan

Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the...
February 05, 2021 02:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 december 2020

VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att förebygga nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda barn....
February 05, 2021 02:00 ET | Source: Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020

Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....